Archives - Page 2

• 

  Volume 1, Issue 2, July 2022

  • Immunotherapy in Hodgkin lymphoma: Current and evolving roles
  • Tailoring therapy in Waldenström Macroglobulinemia
  • Multiple myeloma management: What comes after lenalidomide-based therapy?
  • Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma: A Canadian perspective
  • With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)
• 

  Special Supplement, June 2022

  • Safety and tolerability of Bruton's tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia
• 

  Volume 1, Issue 1, March 2022

  • Next-generation sequencing for myeloid malignancies: Progress and practical applications
  • Management of follicular lymphoma at first relapse
  • Myeloproliferative neoplasms in 2022: A concise review
  • Diagnosis and treatment of AL amyloidosis in 2022
  • To transplant or not to transplant in multiple myeloma
  • Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma